What is Summit Therapeutics's accrued liabilities?

Summit Therapeutics (SMMT) reported accrued liabilities of $12.22M in Q1 2026.

How has Summit Therapeutics's accrued liabilities changed year-over-year?

Summit Therapeutics's accrued liabilities increased by 658.4% year-over-year, from $1.61M to $12.22M.

What is the long-term trend for Summit Therapeutics's accrued liabilities?

Over 3 years (2021 to 2025), Summit Therapeutics's accrued liabilities has grown at a 33.0% compound annual growth rate (CAGR), from $5.49M to $12.93M.

Summit Therapeutics SMMT Accrued liabilities

Accrued liabilities at other companies

Jazz PharmaceuticalsJAZZ

-$7.9M-104%

Roivant SciencesROIV

——

Gilead SciencesGILD

——

BiogenBIIB

——

Other financials

Income statement

See full

Revenue-—

Operating income-$65.6M-81.2%

Net income-$189.4M-201%

EPS (diluted)-$0.24-167%

Balance sheet

See full

Cash & equivalents$8.2M+7.2%

Total debt$20.0M+211%

Total equity$545.9M+58.5%

Total assets$647.9M+68.8%

Cash flow

See full

Operating cash flow-$122.3M-99.9%

CapEx$245.0K-41.9%

Free cash flow-$122.5M-99.0%

Valuation

See full

Market cap$10.67B+3.3%

Enterprise value$10.68B+3.4%

Profitability

See full

Operating margin-268,266.8%-272,316pp

Net margin-271,685%-275,966pp

FCF margin-5,931.6%+4,730pp

Returns & leverage

See full

Return on equity-271%-1,725pp

Debt / equity0×0.0×

Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Summit Therapeutics's accrued liabilities?: Summit Therapeutics (SMMT) reported accrued liabilities of $12.22M in Q1 2026.
How has Summit Therapeutics's accrued liabilities changed year-over-year?: Summit Therapeutics's accrued liabilities increased by 658.4% year-over-year, from $1.61M to $12.22M.
What is the long-term trend for Summit Therapeutics's accrued liabilities?: Over 3 years (2021 to 2025), Summit Therapeutics's accrued liabilities has grown at a 33.0% compound annual growth rate (CAGR), from $5.49M to $12.93M.